Compare Stanley Black & Decker, Inc. (SWK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs TransMedics Group Inc — how do they compare? Stanley Black & Decker, Inc. trades at $91.6 (market cap $14.17B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Stanley Black & Decker, Inc. is far larger — about 4.6× TransMedics Group Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.58% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SWK | TMDX | |
|---|---|---|
Market Cap | $14.17B | $3.06B |
52-Week High | $104.00 | $150.42 |
52-Week Low | $62.12 | $61.99 |
Enterprise Value | $18.33B | $3.46B |
Dividend Yield | 3.58% | — |
Sector | — | Technology |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $93.81, down 3.65% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and management has raised 2026 EPS guidance to $4.60-$5.45. Recent portfolio optimization includes the sale of Excel Industries to Bad Boy Mowers, focusing on core brands. Valuation metrics appear reasonable with P/E of 22.94 and P/S of 0.93, while analyst consensus price target sits at $98.50 with 43% buy ratings.
SWK presents a mixed outlook with strong earnings momentum and cost transformation benefits offset by bearish technical indicators. The stock offers value potential with upside to analyst targets and dividend income, but faces execution risks in margin expansion and industrial demand volatility. Near-term support at $90 provides a key level to watch amid current market weakness.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
